Growth Axis and Syndromes

One year treatment with anastrozole increases predicted adult height in peri-pubertal boys with aggrecan deficiency

ea0110p564 | Growth Axis and Syndromes

Macimorelin test: a safer and reliable alternative to the gold standard insulin tolerance test

ea0110p565 | Growth Axis and Syndromes

Treatment with anastrozole alone or with GH increases final height in pubertal boys with short predicted adult height- real-world data

ea0110p566 | Growth Axis and Syndromes

Effect of a short-term course of transdermal testosterone on growth, puberty and adult height in boys with constitutional delay of growth and puberty (CDGP)

ea0110p567 | Growth Axis and Syndromes

Genetic insights into short stature: an evaluation of clinical, hormonal, and genetic parameters in a real world paediatric cohort

ea0110p568 | Growth Axis and Syndromes

Evaluation of the pharmacokinetics (PK), pharmacodynamics (PD), and safety of the new capsule formulation of LUM-201, an oral growth hormone secretagogue

ea0110p569 | Growth Axis and Syndromes

The need for early reassessment in children with growth hormone deficiency

ea0110p570 | Growth Axis and Syndromes

Long-acting pegylated growth hormone in prepubertal children with turner syndrome: a 3-year multicenter study in China

ea0110p571 | Growth Axis and Syndromes

Gastrointestinal and nutritional challenges in silver-russell syndrome: changes in management and outcomes since 2015

ea0110p572 | Growth Axis and Syndromes

Does pubertal induction with transdermal or oral estrogen have an impact on uterine dimensions in Turner syndrome?

ea0110p573 | Growth Axis and Syndromes

High diagnostic yield of WES in identifying monogenic causes of severe short stature in consanguineous children across three countries: importance of cellular mechanisms in extreme growth disorders

ea0110p574 | Growth Axis and Syndromes

Evolving genetic influences on infant growth: a longitudinal analysis of polygenic scores and growth patterns in infancy

ea0110p575 | Growth Axis and Syndromes

Effects of the ketogenic diet compared to the mediterranean diet in patients with acromegaly

ea0110p576 | Growth Axis and Syndromes

Comparative efficacy of growth hormone, aromatase inhibitors, and gonadotropin-releasing hormone agonists in idiopathic short stature with advanced bone age

ea0110p577 | Growth Axis and Syndromes

Long-acting PEGYlated recombinant human growth hormone (jintrolong) in short children born small for gestational age: 4-year results from a multicenter, randomized, dose-response trial in china

ea0110p578 | Growth Axis and Syndromes

Aetiology of short stature in children originally diagnosed with idiopathic growth hormone deficiency: comprehensive genetic investigation of a single centre cohort

ea0110p579 | Growth Axis and Syndromes

Comparison of oral vs intravenous glucose exposure on plasma growth hormone levels: a crossover study in healthy volunteers

ea0110p580 | Growth Axis and Syndromes

Epidemiology of disorders associated with tall stature in childhood: a 20-year birth cohort study

ea0110p581 | Growth Axis and Syndromes

Liver abnormalities in a population of adult women with turner syndrome

ea0110p582 | Growth Axis and Syndromes

The growth paradox: unraveling the impact of advanced bone age on height potential in untreated conditions"

ea0110p583 | Growth Axis and Syndromes

Efficacy of growth hormone therapy in children with npr2 and acan gene variants: a comparative study

ea0110p584 | Growth Axis and Syndromes

Efficacy of somapacitan in treatment-fatigue adults with growth hormone deficiency previously treated with daily GH injections: a 24-week randomized active-controlled trial

ea0110p585 | Growth Axis and Syndromes

Long-term maintenance in the upper normal IGF-1 levels has beneficial effects on body fat and marker of low-grade inflammation in adults with growth hormone deficiency

ea0110p586 | Growth Axis and Syndromes

Analysis of functionally uncharacterized variants of the GH1 gene from patients with isolated growth hormone deficiency (IGHD)

ea0110p587 | Growth Axis and Syndromes

Retrospective evaluation of the phenotypic-genotypic characteristics of patients with short stature who underwent next-generation sequencing analysis

ea0110p588 | Growth Axis and Syndromes

The impact of dose modification guided by growth response monitoring on igf-1 levels and height velocity in growth hormone deficiency treatment

ea0110p589 | Growth Axis and Syndromes

Real-world IGF-I variations & its management in children on recombinant human growth hormone (rhGH) therapy (RIGHT study)

ea0110p590 | Growth Axis and Syndromes

Unexpected high frequency of copy number variations as genetic causes of failure to achieve catch-up growth in small for gestational age children: a multicenter study in Korea

ea0110p591 | Growth Axis and Syndromes

Spinal deformities in patients with rasopathies and pathogenic variants in related genes

ea0110p592 | Growth Axis and Syndromes

A genetic cause of tall stature is more often detected in children with familial tall stature compared to non-familial tall stature

ea0110p593 | Growth Axis and Syndromes

Combined human growth hormone and gonadotropin-releasing hormone analog therapy improves pubertal growth in children with poor final height prognosis: a retrospective observational study

ea0110p594 | Growth Axis and Syndromes

Development of muscle function in children with achondroplasia under vosoritide treatment

ea0110p595 | Growth Axis and Syndromes

SEENEZ-trial: cost-analysis of withdrawing growth hormone treatment at mid-puberty in adolescents with transient idiopathic isolated growth hormone deficiency

ea0110p596 | Growth Axis and Syndromes

Impact of methylphenidate on growth, thyroid function, and cortisol secretion in children with ADD/ADHD: a systematic review (2000–2024)

ea0110p597 | Growth Axis and Syndromes

Long-term growth hormone therapy in a patient with hallermann-streiff syndrome: a 15-year follow-up

ea0110p598 | Growth Axis and Syndromes

Short stature and growth hormone deficiency in a case of POMC deficiency: an unexpected clinical association

ea0110p599 | Growth Axis and Syndromes

Impact of the TUITEK™ patient support program on caregivers-related behaviours in enhancing growth hormone treatment adherence

ea0110p600 | Growth Axis and Syndromes

A novel point-of-care molecular diagnostic method for the rapid diagnosis of Turner syndrome

ea0110p601 | Growth Axis and Syndromes

Genotype-phenotype correlations and clinical variability in noonan syndrome

ea0110p602 | Growth Axis and Syndromes

Is the high incidence of false-positive results of growth hormone stimulation tests in children with short stature related to the nutritional status? Let’s ask artificial intelligence

ea0110p603 | Growth Axis and Syndromes

The medical impact of hypochondroplasia by age among adults in England between 1998 and 2019: a matched cohort study using electronic medical records from the clinical practice research datalink

ea0110p604 | Growth Axis and Syndromes

Screening for shox gene variation in children with apparently idiopathic short stature: systematic screening or clinical and radiological oriented screening?

ea0110p605 | Growth Axis and Syndromes

Long term follow-up in a patient with Cat Eye syndrome, hypopituitarism and hypertransaminasemia

ea0110p606 | Growth Axis and Syndromes

Quality of life, sexuality, and psychosocial well-being in adult women with turner syndrome: insights from a danish questionnaire survey

ea0110p607 | Growth Axis and Syndromes

Total and bioactive IGF-i in healthy children and adolescents and in short children during growth hormone therapy: an alternative tool to individualized GH treatment in patients

ea0110p608 | Growth Axis and Syndromes

Frequency, detection and management of scoliosis in children with prader willi syndrome – experience of an irish tertiary referral centre

ea0110p609 | Growth Axis and Syndromes

Characterization of bone health in an adult population with turner syndrome: insights from a monocentric cross-sectional study

ea0110p610 | Growth Axis and Syndromes

Prevalence and growth pattern of poor long-term responders to gh therapy in prepubertal short children born small for gestational age: real life data from them belgian-luxembourgish registry BELGROW

ea0110p611 | Growth Axis and Syndromes

Advancing precision in GH therapy: AI models for predicting IGF-1

ea0110p612 | Growth Axis and Syndromes

EKAT-06 evidence based knowledge for monitoring childhood growth

ea0110p613 | Growth Axis and Syndromes

Evaluation of growth velocity in patients with achondroplasia treated with vosoritide

ea0110p614 | Growth Axis and Syndromes

Comparison of the effects of weekly and daily treatment on auxology, metabolism and quality of life in cases with growth hormone deficiency

ea0110p615 | Growth Axis and Syndromes

Use of vosoritide in children with achondroplasia - clinical experience

ea0110p616 | Growth Axis and Syndromes

Treatment in genetic short stature: growth hormone use in patients with npr2 heterozygous variants

ea0110p617 | Growth Axis and Syndromes

The medical impact of hypochondroplasia among children in England between 1998 and 2019: a matched cohort study using electronic medical records from the clinical practice research datalink

ea0110p618 | Growth Axis and Syndromes

Diagnosis of silver russell syndrome in 2025: is a scoring system still helpful?

ea0110p619 | Growth Axis and Syndromes

GloBE-Reg: A global registry for evaluating the safety and effectiveness of growth hormone therapy across the age span

ea0110p620 | Growth Axis and Syndromes

Clinical characteristics of children with mccune–albright syndrome in China: a retrospective cohort study

ea0110p621 | Growth Axis and Syndromes

When genetics cast doubt on paternity

ea0110p622 | Growth Axis and Syndromes

Impact of body mass index on growth hormone peak during insulin tolerance test in childrenand adolescents

ea0110p623 | Growth Axis and Syndromes

Unraveling the genetic basis of short stature in pediatric patients: a whole exome sequencing approach

ea0110p624 | Growth Axis and Syndromes

N-acetylcysteine treatment for skin-picking in children and young adults with pws: a randomized placebo-controlled cross-over trial

ea0110p625 | Growth Axis and Syndromes

Challenges of puberty in turner syndrome: experience of a tertiary pediatric hospital

ea0110p626 | Growth Axis and Syndromes

Quality of life improvements with GH, GnRHa, and AI therapies in children with short stature and advanced bone age

ea0110p627 | Growth Axis and Syndromes

Effect of growth hormone therapy on final height in SHOX deficiency and turner syndrome: a single-center experience

ea0110p628 | Growth Axis and Syndromes

Retrospective analysis of two databases on growth hormone treatment in chinese children with short stature – baseline characteristics and clinical inertia

ea0110p629 | Growth Axis and Syndromes

Identifying relevant factors for recommendation of digital health solutions supporting paediatric growth hormone treatments in Finland: insights from participatory workshop

ea0110p630 | Growth Axis and Syndromes

Continuous glucose monitoring (CGM) for assessing glycaemic variability in growth hormone deficient children shifting from recombinant GH daily injections to long-acting GH analogues: a case series

ea0110p631 | Growth Axis and Syndromes

Comparison of leptin, ghrelin, and nesfatin levels in growth hormone deficiency and short stature patients before and after growth hormone therapy

ea0110p632 | Growth Axis and Syndromes

Growth hormone therapy in noonan syndrome: impact on neurodevelopment and prognosis

ea0110p633 | Growth Axis and Syndromes

Mysoconnect® for sogroya®: long-acting growth hormone for patients with growth-related disorders and their caregivers

ea0110p634 | Growth Axis and Syndromes

Efficacy and safety of somapacitan vs daily growth hormone at 52 weeks in patients with growth hormone deficiency: pooled analysis of the randomised REAL 3, REAL 4 and REAL 6 clinical trials

ea0110p635 | Growth Axis and Syndromes

Evaluation of features for a digital application for growth hormone therapy using perceptions gathered from patients, caregivers and healthcare professionals

ea0110p636 | Growth Axis and Syndromes

Real-world data: effectiveness and safety of vosoritide in the treatment of achondroplasia in chinese population

ea0110p637 | Growth Axis and Syndromes

Long-acting PEG-RHGH: insights from five-year outcomes in pediatric patients with growth hormone deficiency from CGLS database

ea0110p638 | Growth Axis and Syndromes

Clinical delineation and genotype-phenotype correlation in 104 pediatric patients with kabuki syndrome: a large longitudinal cohort from a single center in china

ea0110p639 | Growth Axis and Syndromes

Early growth hormone treatment enhances growth and nutritional status in silver-russell syndrome

ea0110p640 | Growth Axis and Syndromes

The impact of growth retardation on quality of life

ea0110p641 | Growth Axis and Syndromes

Assessing skeletal maturity in indian children: a comparative study of GP, GR, and TW3 methods

ea0110p642 | Growth Axis and Syndromes

Factors influencing growth trajectory and adult height in children born small for gestational age and treated with growth hormone: a single center study

ea0110p643 | Growth Axis and Syndromes

Childhood-onset growth hormone deficiency: transition from pediatric to adult endocrine care in the Netherlands

ea0110p644 | Growth Axis and Syndromes

Effects of growth hormone (GH) and sex steroid therapy on brain structure and pituitary function in turner syndrome (TS)

ea0110p645 | Growth Axis and Syndromes

Growth hormone therapy in children with congenital acyanotic heart disease and short stature: balancing growth and cardiac health

ea0110p646 | Growth Axis and Syndromes

Should the initial dose of long-acting growth hormone therapy somatrogon for pediatric growth hormone deficiency be standard for each child?

ea0110p647 | Growth Axis and Syndromes

Design of a phase 2, randomized, controlled, multicentre study of vosoritide treatment in children with idiopathic short stature

ea0110p648 | Growth Axis and Syndromes

Phase 3 pivotal trial design of daily oral LUM-201’s efficacy and safety in treatment-naïve children with growth hormone deficiency (GHD) in randomized, double-blind, placebo-controlled study

ea0110p649 | Growth Axis and Syndromes

Changes in body composition, ghrelin, adipokines, and FGF23 in growth hormone deficient children during rhGH therapy

ea0110p650 | Growth Axis and Syndromes

Big data as a strategy in the development of population auxological studies

ea0110p651 | Growth Axis and Syndromes

Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

BiosciAbstracts